Continuum Advisory LLC Purchases 6,149 Shares of Medtronic PLC $MDT

Continuum Advisory LLC raised its position in shares of Medtronic PLC (NYSE:MDT) by 24.6% in the fourth quarter, Holdings Channel reports. The fund owned 31,123 shares of the medical technology company’s stock after buying an additional 6,149 shares during the quarter. Continuum Advisory LLC’s holdings in Medtronic were worth $2,990,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also made changes to their positions in MDT. Norges Bank bought a new stake in shares of Medtronic in the fourth quarter valued at about $1,653,485,000. Barclays PLC lifted its stake in shares of Medtronic by 104.6% in the third quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock valued at $650,604,000 after buying an additional 3,492,192 shares during the period. Schroder Investment Management Group lifted its stake in shares of Medtronic by 78.3% in the third quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company’s stock valued at $717,143,000 after buying an additional 3,307,211 shares during the period. Guinness Asset Management LTD bought a new stake in shares of Medtronic in the third quarter valued at about $275,556,000. Finally, Wellington Management Group LLP lifted its stake in shares of Medtronic by 35.3% in the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock valued at $970,456,000 after buying an additional 2,658,981 shares during the period. Institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Barclays increased their target price on shares of Medtronic from $118.00 to $120.00 and gave the company an “overweight” rating in a research note on Wednesday, April 1st. Royal Bank Of Canada reiterated an “outperform” rating and issued a $118.00 target price on shares of Medtronic in a research note on Thursday. Mizuho cut their price target on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating for the company in a research note on Wednesday. Daiwa Securities Group cut their price target on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Finally, Weiss Ratings cut shares of Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, May 21st. Sixteen investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $98.70.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic beat fiscal Q4 revenue and earnings estimates, driven by strong demand in cardiovascular devices, cardiac ablation, and medical-surgical products, which helped fuel the stock’s rebound.
• Positive Sentiment: The company raised its quarterly dividend to $0.72 per share, signaling confidence in cash generation and rewarding income-focused investors.
• Positive Sentiment: Management highlighted expanded Hugo robotic-assisted surgery filings and FDA activity, suggesting additional growth opportunities in surgical robotics. Medtronic submits 510(k) filings to expand Hugo robotic-assisted surgery system into general and gynecologic specialties in the United States
• Positive Sentiment: Several analysts maintained or upgraded bullish views, including BTIG’s upgrade to Buy and TD Cowen’s reiterated Buy, reinforcing optimism after the earnings beat. Wall Street May Be Mispricing Medtronic, Analyst Says
• Neutral Sentiment: Some analysts trimmed price targets while keeping neutral or hold ratings, including JPMorgan, Piper Sandler, Goldman Sachs, Baird, and Deutsche Bank, which reflects more cautious valuation views rather than a major change in the long-term story.
• Neutral Sentiment: Medtronic is also managing cardiovascular device recalls tied to sterile barrier concerns, creating an ongoing overhang even as newer product launches gain traction.
• Negative Sentiment: FY2027 EPS guidance came in slightly below the consensus estimate, and management noted tariff-related and margin pressure concerns, which may limit further upside. MDT Q4 Earnings Call Points to Another Year of Growth

Medtronic Stock Up 5.1%

Shares of MDT opened at $81.95 on Friday. The stock has a market cap of $105.22 billion, a price-to-earnings ratio of 21.97, a P/E/G ratio of 1.89 and a beta of 0.58. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12 month low of $73.31 and a 12 month high of $106.33. The company has a 50-day moving average price of $81.58 and a two-hundred day moving average price of $92.11.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. The firm had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.61%. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities analysts predict that Medtronic PLC will post 5.97 EPS for the current fiscal year.

Medtronic Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 annualized dividend and a dividend yield of 3.5%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).